Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorKaplancıklı, Zafer Asım
dc.contributor.authorSever, Belgin
dc.contributor.authorAltıntop, Mehlika Dilek
dc.contributor.authorAtlı Eklioğlu, Özlem
dc.contributor.authorBaysal, Merve
dc.contributor.authorÖzdemir, Ahmet
dc.date.accessioned2019-10-19T14:44:30Z
dc.date.available2019-10-19T14:44:30Z
dc.date.issued2017
dc.identifier.issn1570-1808
dc.identifier.issn1875-628X
dc.identifier.urihttps://dx.doi.org/10.2174/1570180814666161104161711
dc.identifier.urihttps://hdl.handle.net/11421/13534
dc.descriptionWOS: 000404984700004en_US
dc.description.abstractBackground: In recent years, thiazole derivatives incorporated with hydrazone moiety have attracted a great deal of interest due to their pivotal role in the field of current cancer research. Methods: In the present study, new thiazolyl hydrazone derivatives were synthesized via the reaction of 1-(4-phenylcyclohexylidene) thiosemicarbazide with 2-bromoacetophenone derivatives. MTT assay was performed to assess the cytotoxic effects of the compounds on A549 human lung adenocarcinoma, HepG2 human liver hepatocellular carcinoma and C6 rat glioma cell lines. The selectivity of the compounds was investigated using NIH/3T3 mouse embryonic fibroblast cell line. Results: 4-(4-Methylsulfonylphenyl)-2-(2-(4-phenylcyclohexylidene)hydrazinyl) thiazole (7) was found to be the most promising anticancer agent against HepG2 cell line with an IC50 value of 0.316 mM when compared with cisplatin (IC50=0.091 mM). Compounds 2 and 6 also exhibited cytotoxic effects on HepG2 cell line with IC50 values of 0.81 mM and 0.79 mM, respectively. Besides, compounds 2, 6 and 7 did not show any cytotoxicity against NIH/3T3 cell line. Conclusion: In particular, compound 7 was found to be a potent anticancer agent to go further studies due to its selective antitumor activity against HepG2 cell line.en_US
dc.description.sponsorshipAnadolu University Scientific Research Projects Commission [1605S318]en_US
dc.description.sponsorshipThis study was supported by the Anadolu University Scientific Research Projects Commission under the grant no: 1605S318.en_US
dc.language.isoengen_US
dc.publisherBentham Science Publ LTDen_US
dc.relation.isversionof10.2174/1570180814666161104161711en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnticancer Activityen_US
dc.subjectThiazoleen_US
dc.subjectHydrazoneen_US
dc.subjectHepatocellular Carcinomaen_US
dc.subjectGliomaen_US
dc.subjectAnticancer Agenten_US
dc.titleSynthesis and Evaluation of New Thiazolyl Hydrazone Derivatives as Potential Anticancer Agentsen_US
dc.typearticleen_US
dc.relation.journalLetters in Drug Design & Discoveryen_US
dc.contributor.departmentAnadolu Üniversitesi, Eczacılık Fakültesi, Farmasötik Kimya Anabilim Dalıen_US
dc.identifier.volume14en_US
dc.identifier.issue6en_US
dc.identifier.startpage672en_US
dc.identifier.endpage677en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.contributor.institutionauthorKaplancıklı, Zafer Asım
dc.contributor.institutionauthorSever, Belgin
dc.contributor.institutionauthorAltıntop, Mehlika Dilek
dc.contributor.institutionauthorAtlı Eklioğlu, Özlem
dc.contributor.institutionauthorÖzdemir, Ahmet


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster